Vericel Reports Significant Earnings Growth in Q4
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy VCEL?
Source: NASDAQ.COM
- Earnings Performance: Vericel Corporation reported a net income of $23.24 million for Q4, translating to an earnings per share (EPS) of $0.45, which marks a significant increase from last year's $19.81 million and $0.38 EPS, indicating enhanced competitiveness in the market.
- Significant Revenue Growth: The company's revenue surged by 23.3% year-over-year to $92.92 million, up from $75.38 million last year, demonstrating strong product demand and an expanding market share.
- Improved Financial Health: With both revenue and earnings on the rise, Vericel's financial health has markedly improved, enhancing its investment appeal in the biopharmaceutical sector and providing stronger funding support for future R&D and market expansion.
- Optimistic Market Outlook: The performance boost not only reflects current market demand but also lays a foundation for future growth, likely attracting more investor attention and further driving stock price appreciation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VCEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VCEL
Wall Street analysts forecast VCEL stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 35.680
Low
55.00
Averages
57.67
High
60.00
Current: 35.680
Low
55.00
Averages
57.67
High
60.00
About VCEL
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vericel Corporation Reports Strong Q4 2025 Earnings with Record Revenue Growth
- Record Financial Performance: Vericel Corporation reported fourth quarter total revenue of $92.9 million, reflecting a 23% year-over-year growth, with full-year revenue reaching $276.3 million, exceeding expectations and showcasing the company's strong market performance and profitability.
- Significant MACI Sales Growth: The MACI product line generated over $84.1 million in revenue during Q4, marking a 23% increase compared to the previous year and a 51% sequential growth, indicating substantial progress in expanding market share and product acceptance.
- Strategic Investments and Expansion: The company plans to continue expanding its MACI sales force in 2026 while advancing the MACI Ankle clinical study and international market expansion, with projected MACI revenue guidance of $280 million to $286 million for the full year, reflecting confidence in future growth.
- Cash Flow and Financial Health: By the end of 2025, the company reported approximately $200 million in cash and investments with no debt, alongside an operating cash flow of $52 million for the year, demonstrating robust financial management and operational efficiency.
See More
Vericel Reports Significant Earnings Growth in Q4
- Earnings Performance: Vericel Corporation reported a net income of $23.24 million for Q4, translating to an earnings per share (EPS) of $0.45, which marks a significant increase from last year's $19.81 million and $0.38 EPS, indicating enhanced competitiveness in the market.
- Significant Revenue Growth: The company's revenue surged by 23.3% year-over-year to $92.92 million, up from $75.38 million last year, demonstrating strong product demand and an expanding market share.
- Improved Financial Health: With both revenue and earnings on the rise, Vericel's financial health has markedly improved, enhancing its investment appeal in the biopharmaceutical sector and providing stronger funding support for future R&D and market expansion.
- Optimistic Market Outlook: The performance boost not only reflects current market demand but also lays a foundation for future growth, likely attracting more investor attention and further driving stock price appreciation.
See More
Vericel Q4 Earnings Exceed Expectations with Strong Revenue Growth
- Strong Earnings Report: Vericel's Q4 GAAP EPS of $0.45 beats expectations by $0.06, indicating a sustained enhancement in profitability and reflecting the company's competitive position in the market.
- Significant Revenue Growth: The total revenue reached $92.92 million, representing a 23.2% year-over-year increase and surpassing market expectations by $0.26 million, showcasing Vericel's success in product demand and market expansion.
- MACI Revenue Performance: MACI® net revenue grew by 23% to $84.1 million, further solidifying its market position in regenerative medicine and is expected to drive future revenue growth.
- Future Financial Guidance: Vericel anticipates total revenue between $316 million and $326 million for 2026, with MACI revenue projected between $280 million and $286 million, demonstrating the company's confidence and strategic planning for future growth.
See More
Vericel Scheduled to Announce Q4 Earnings on February 26
- Earnings Announcement Schedule: Vericel is set to release its Q4 earnings on February 26 before market open, with a consensus EPS estimate of $0.38, indicating stable profitability compared to last year.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $92.66 million, reflecting a 22.9% year-over-year increase, showcasing the company's growth potential and rising product demand despite competitive pressures in the industry.
- Estimate Revision Dynamics: Over the past three months, EPS estimates have seen no upward revisions and one downward revision, while revenue estimates experienced one upward revision, indicating analysts' cautious outlook on the company's future performance, which may affect investor confidence.
- Long-Term Revenue Outlook: Vericel expects to achieve $276 million in revenue by 2025, suggesting that despite short-term challenges, the company remains confident in its strategic planning and future growth prospects.
See More
Vericel Corporation (VCEL) Expects $276 Million Revenue in 2025 with Continued Profitability
- Financial Outlook: Vericel anticipates total net revenue of approximately $276 million for 2025, with MACI net revenue of $239.5 million, reflecting a 23% growth in Q4, indicating sustained competitive strength in the market.
- Profitability Improvement: The company expects to achieve GAAP net income profitability for the second consecutive year, supported by a gross margin of 74%, which will provide robust financial backing for future investments and expansions.
- Operational Achievements: Vericel has reached a quarterly record in MACI implants and trained surgeons, with over 900 MACI-trained surgeons, and plans to commence commercial manufacturing in a new facility in 2026, showcasing strong growth potential.
- Market Performance: Despite a downturn in the broader market, Vericel's stock rose 2.92% to $37.66, reflecting unique company-specific momentum, although the stock has decreased by 36.77% over the past 12 months.
See More
VCEL Stock Shows Significant Volatility with 52-Week High of $63
- Stock Price Analysis: VCEL's 52-week low is $29.24, with a high of $63, and the last trade at $38.11 indicates significant volatility over the past year, reflecting varying market expectations regarding its future performance.
- Market Trend Observation: The current price of $38.11 is close to the 52-week low, suggesting a cautious investor sentiment towards the company's growth prospects, while potentially providing a window for buying opportunities.
- Technical Indicator Focus: VCEL's stock has crossed above its 200-day moving average, indicating a possible short-term rebound trend that has caught the attention of technical analysts, which may influence investor trading decisions.
- Investor Sentiment Assessment: Despite the current price being below the 52-week high, market views on VCEL remain diverse, necessitating investors to monitor fundamental changes in the company to make more informed investment decisions.
See More
Vericel Corporation Reports Strong Q4 2025 Earnings with Record Revenue Growth
- Record Financial Performance: Vericel Corporation reported fourth quarter total revenue of $92.9 million, reflecting a 23% year-over-year growth, with full-year revenue reaching $276.3 million, exceeding expectations and showcasing the company's strong market performance and profitability.
- Significant MACI Sales Growth: The MACI product line generated over $84.1 million in revenue during Q4, marking a 23% increase compared to the previous year and a 51% sequential growth, indicating substantial progress in expanding market share and product acceptance.
- Strategic Investments and Expansion: The company plans to continue expanding its MACI sales force in 2026 while advancing the MACI Ankle clinical study and international market expansion, with projected MACI revenue guidance of $280 million to $286 million for the full year, reflecting confidence in future growth.
- Cash Flow and Financial Health: By the end of 2025, the company reported approximately $200 million in cash and investments with no debt, alongside an operating cash flow of $52 million for the year, demonstrating robust financial management and operational efficiency.
See More
Vericel Reports Significant Earnings Growth in Q4
- Earnings Performance: Vericel Corporation reported a net income of $23.24 million for Q4, translating to an earnings per share (EPS) of $0.45, which marks a significant increase from last year's $19.81 million and $0.38 EPS, indicating enhanced competitiveness in the market.
- Significant Revenue Growth: The company's revenue surged by 23.3% year-over-year to $92.92 million, up from $75.38 million last year, demonstrating strong product demand and an expanding market share.
- Improved Financial Health: With both revenue and earnings on the rise, Vericel's financial health has markedly improved, enhancing its investment appeal in the biopharmaceutical sector and providing stronger funding support for future R&D and market expansion.
- Optimistic Market Outlook: The performance boost not only reflects current market demand but also lays a foundation for future growth, likely attracting more investor attention and further driving stock price appreciation.
See More
Vericel Q4 Earnings Exceed Expectations with Strong Revenue Growth
- Strong Earnings Report: Vericel's Q4 GAAP EPS of $0.45 beats expectations by $0.06, indicating a sustained enhancement in profitability and reflecting the company's competitive position in the market.
- Significant Revenue Growth: The total revenue reached $92.92 million, representing a 23.2% year-over-year increase and surpassing market expectations by $0.26 million, showcasing Vericel's success in product demand and market expansion.
- MACI Revenue Performance: MACI® net revenue grew by 23% to $84.1 million, further solidifying its market position in regenerative medicine and is expected to drive future revenue growth.
- Future Financial Guidance: Vericel anticipates total revenue between $316 million and $326 million for 2026, with MACI revenue projected between $280 million and $286 million, demonstrating the company's confidence and strategic planning for future growth.
See More
Vericel Scheduled to Announce Q4 Earnings on February 26
- Earnings Announcement Schedule: Vericel is set to release its Q4 earnings on February 26 before market open, with a consensus EPS estimate of $0.38, indicating stable profitability compared to last year.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $92.66 million, reflecting a 22.9% year-over-year increase, showcasing the company's growth potential and rising product demand despite competitive pressures in the industry.
- Estimate Revision Dynamics: Over the past three months, EPS estimates have seen no upward revisions and one downward revision, while revenue estimates experienced one upward revision, indicating analysts' cautious outlook on the company's future performance, which may affect investor confidence.
- Long-Term Revenue Outlook: Vericel expects to achieve $276 million in revenue by 2025, suggesting that despite short-term challenges, the company remains confident in its strategic planning and future growth prospects.
See More
Vericel Corporation (VCEL) Expects $276 Million Revenue in 2025 with Continued Profitability
- Financial Outlook: Vericel anticipates total net revenue of approximately $276 million for 2025, with MACI net revenue of $239.5 million, reflecting a 23% growth in Q4, indicating sustained competitive strength in the market.
- Profitability Improvement: The company expects to achieve GAAP net income profitability for the second consecutive year, supported by a gross margin of 74%, which will provide robust financial backing for future investments and expansions.
- Operational Achievements: Vericel has reached a quarterly record in MACI implants and trained surgeons, with over 900 MACI-trained surgeons, and plans to commence commercial manufacturing in a new facility in 2026, showcasing strong growth potential.
- Market Performance: Despite a downturn in the broader market, Vericel's stock rose 2.92% to $37.66, reflecting unique company-specific momentum, although the stock has decreased by 36.77% over the past 12 months.
See More
VCEL Stock Shows Significant Volatility with 52-Week High of $63
- Stock Price Analysis: VCEL's 52-week low is $29.24, with a high of $63, and the last trade at $38.11 indicates significant volatility over the past year, reflecting varying market expectations regarding its future performance.
- Market Trend Observation: The current price of $38.11 is close to the 52-week low, suggesting a cautious investor sentiment towards the company's growth prospects, while potentially providing a window for buying opportunities.
- Technical Indicator Focus: VCEL's stock has crossed above its 200-day moving average, indicating a possible short-term rebound trend that has caught the attention of technical analysts, which may influence investor trading decisions.
- Investor Sentiment Assessment: Despite the current price being below the 52-week high, market views on VCEL remain diverse, necessitating investors to monitor fundamental changes in the company to make more informed investment decisions.
See More
